HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
Departamento
Universidad de Córdoba
Córdoba, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Córdoba (8)
2022
-
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
European Journal of Cancer, Vol. 161, pp. 26-37
2019
-
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
Translational Neurodegeneration, Vol. 8, Núm. 1
2018
-
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)
Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111
-
Severe, life-threatening phenotype of primary Sjögren's syndrome: Clinical characterisation and outcomes in 1580 patients (the GEAS-SS Registry)
Clinical and Experimental Rheumatology, Vol. 36, pp. S121-S129
2015
-
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137
2006
-
The hypothalamus-pituitary-ovarian axis as a model system for the study of SERM effects: An overview of experimental and clinical studies
Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs (Springer Berlin Heidelberg), pp. 103-139
2003
-
Effect of treatment with the selective oestrogen receptor modulator LY117018-HCl on pituitary sensitivity to GnRH and subsequent ovulation
Reproduction, Vol. 125, Núm. 4, pp. 597-606
1992
-
Peripheral stent recovery after failed intracoronary delivery
Catheterization and Cardiovascular Diagnosis, Vol. 27, Núm. 3, pp. 230-233